SCHEMBL167090

SCHEMBL167090

COc1ccc(Br)c(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.62
CA1 P00915 2/20 0.62
CA2 P00918 2/20 0.62
CA7 P43166 2/20 0.62
CA9 Q16790 2/20 0.62
CA14 Q9ULX7 2/20 0.62
CYP1A1 P04798 8/20 0.54
CYP1B1 Q16678 8/20 0.54
CYP1A2 P05177 7/20 0.54
ALDH1A1 P00352 5/20 0.54
CYP3A4 P08684 2/20 0.54
CYP2E1 P05181 1/20 0.53
CYP2C8 P10632 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2A6 P11509 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP4B1 P13584 1/20 0.53
CYP2B6 P20813 1/20 0.53
CYP3A5 P20815 1/20 0.53
CYP2A7 P20853 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14127541 1.00 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL29558143 1.00 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL7403167 0.98 CA12 (0.60) CA12CA1CA2CA7CA9
SCHEMBL9383598 0.94 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL7819014 0.85 CA12 (0.45) CA12CA1CA2CA7CA9
SCHEMBL29634588 0.83 CA12 (0.65) CA12CA1CA2CA7CA9
SCHEMBL258418 0.83 CA12 (0.65) CA12CA1CA2CA7CA9
SCHEMBL6449465 0.83 CA1 (0.48) CA12CA1CA2CA7CA9
SCHEMBL12003966 0.83 CA12 (0.43) CA12CA1CA2CA7CA9
SCHEMBL30250475 0.82 CA1 (0.53) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113651832-B Method for synthesizing optically pure glabridin 河北工业大学 2022-08-16 CN claimed
CN-113637022-B Method for synthesizing glabridin 河北工业大学 2022-07-19 CN claimed
CN-111362961-B Method for asymmetrically synthesizing optical purity glabridin 玉林师范学院 2021-12-10 CN claimed
CN-113651832-A Method for synthesizing optically pure glabridin 河北工业大学 2021-11-16 CN claimed
CN-113637022-A Method for synthesizing glabridin 河北工业大学 2021-11-12 CN claimed
CN-111825715-A Synthesis method of triphenylphosphine derivative tri- (R-phenyl) phosphine 江苏富比亚化学品有限公司 2020-10-27 CN claimed
CN-111362961-A Method for asymmetrically synthesizing optical purity glabridin 玉林师范学院 2020-07-03 CN claimed
CN-109879732-A A kind of preparation method of 1- (5- isopropyl -2,4- Dimethoxyphenyl) ethyl ketone 上海卡洛化学有限公司 2019-06-14 CN claimed
US-20260102762-A1 TRI-(ADAMANTYL)PHOSPHINES AND APPLICATIONS THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2026-04-16 US disclosed
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
US-12539508-B2 Tri-(adamantyl) phosphines and applications thereof THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2026-02-03 US disclosed
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-12509479-B2 P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2025-12-30 US disclosed
US-4487934-A Method of preparing poly-substituted acylbenzenes HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1984-12-11 US disclosed
US-4457875-A ANTIDEPRESSANTS, TRANQUILIZERS CHOAY S.A. (FR) 1984-07-03 US disclosed
EP-0041682-B1 A METHOD OF PREPARING POLY-SUBSTITUTED ACYLBENZENES HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1983-09-21 EP disclosed
EP-0045478-A1 A method of preparing poly-substituted acylbenzenes HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1982-02-10 EP disclosed
EP-0041682-A1 A method of preparing poly-substituted acylbenzenes HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1981-12-16 EP disclosed
US-4304941-A Method of preparing poly-substituted acylbenzenes HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) 1981-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12539508-B2 Tri-(adamantyl) phosphines and applications thereof OTC, AOC3, ICOSLG CA12 179/4885CA1 225/4885CA2 235/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B CA12 906/4885CA1 1778/4885CA2 199/4885
US-20260102762-A1 TRI-(ADAMANTYL)PHOSPHINES AND APPLICATIONS THEREOF PTMS, TEC, CD2 CA12 1142/4885CA1 598/4885CA2 987/4885
US-12509479-B2 P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof P2RX3, P2RX6, P2RX2 CA12 3354/4885CA1 2186/4885CA2 683/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B CA12 4276/4885CA1 2723/4885CA2 3408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.